ClinicalTrials.gg
RecruitingNCT06251258REFIREUpdated Apr 6, 2026

Facial Emotion Recognition in Insomnia and Emotional Regulation

An interventional study of Facial emotion recognition test with and without eye-tracking and Cognitive Emotion Regulation. Questionnaire (CERQ) in Chronic Insomnia, sponsored by University Hospital, Angers. Recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by University Hospital, Angers · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
128
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Sleep Initiation and Maintenance Disorders with a site in France — 19 open to participants now, 19 under way, 1 of them phase 3. Sleep Initiation and Maintenance Disorders · France.

Planned enrollment
23rd of 60
128 · median 69
Started
2025
with 7 others
No phase
37 of 76
12 open now
Primary completion
2027-09
later than 9 of 18 live
Registered
61st of 76
by date

Among the 76 studies in Sleep Initiation and Maintenance Disorders with a site in France, this one is the 23rd largest by planned enrollment of the 60 interventional ones that give a count, is one of 8 that started in 2025, is one of 37 with no phase, reaches primary completion later than 9 of the 18 other live ones, and was the 61st registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

19 of the 76 studies in Sleep Initiation and Maintenance Disorders with a site in France are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Sleep Initiation and Maintenance Disorders with a site in France, or all of them as a file.
02

Study summary

Introduction Chronic insomnia is a prevalent disorder in the general population, affecting up to 20% according to French National Institute of Health and Medical Research, leading to a decline in quality of life and an increased risk of developing certain psychiatric disorders, notably major depressive episodes. Chronic insomnia, particularly when accompanied by reduced sleep duration, has been associated with cognitive impairments documented in the literature, such as reduced concentration, working memory, vigilance, and certain executive functions.

While some studies suggest subjective cognitive impairment in insomnia, it remains inconclusive when objectively measured. Individuals with chronic insomnia often report a global deterioration in social life, characterized by irritability, attentional difficulties, asthenia, and social isolation. This raises questions about potential impairments in social abilities, particularly in recognizing facial emotions, which may be linked to the subjective complaints of reduced quality of life in individuals with insomnia.

Several studies have explored facial emotion recognition in insomnia, with some indicating impairments in emotion recognition or evaluation of emotion intensity. Others demonstrated deficits in recognizing specific emotions (such as anger) or representations (such as fatigue), which were associated with attentional deficits and changes in visual fixation points in eye-tracking studies.

However, some authors found no significant association between insomnia complaints and impaired facial emotion recognition. Facial emotion recognition has been studied using eye-tracking in major depressive episodes, attention-deficit/hyperactivity disorder (ADHD), and autism spectrum disorders. Eye-tracking studies have revealed attentional biases toward negative emotions in depression and deficits in visual attention to the eye region in autism, contributing to impaired facial emotion recognition. To date, no study has compared facial emotion recognition abilities between individuals with insomnia and a control group, considering attentional deficits and emotional dysregulation described in insomnia.

Methods The study aims to compare two groups: one with isolated insomnia (without associated psychiatric disorders) and a control group (without insomnia or psychiatric disorders). Patients with psychiatric or addictive disorders will be excluded based on Diagnostic and Statistical Manual of Mental Disorders, version 5 (DSM-V) psychiatric interviews. Participants aged over 65 or under 18 will also be excluded to mitigate potential biases related to dementia and cognitive alterations not related to insomnia.

The insomnia group will consist of individuals seeking care at the Sleep Center of Angers University Hospital for chronic insomnia (lasting more than 3 months). Insomnia will be confirmed using the Insomnia Severity Index (ISI), with a score exceeding 15, while individuals with subclinical insomnia (ISI score between 7 and 15) will be excluded. The control group will have an ISI score below 7 (indicating the absence of insomnia).

The main objective is to determine whether facial emotion recognition differs between the insomnia and control groups. Secondary objectives include assessing differences between explicit facial emotion recognition tests (controlled conditions) and eye-tracking tests (implicit memory) in both groups to evaluate attentional biases. Additionally, the study aims to explore differences in facial emotion recognition tests based on emotional regulation profiles (adaptive or non-adaptive regulation).

Expected Results The hypothesis is that facial emotion recognition under controlled conditions (explicit memory) will not differ between the insomnia and control groups. However, differences are expected in implicit memory tests (eye-tracking) due to the attentional deficits previously described in insomnia. Additionally, variations in facial emotion recognition are anticipated based on emotional regulation profiles, which may influence facial emotion recognition in insomnia.

The study's findings could contribute to a better understanding of cognitive complaints related to insomnia, especially in the realm of social interactions, by objectively assessing and specifying potential biases. This research may also inform targeted therapeutic approaches, particularly in cognitive-behavioral therapy, focusing on cognitive remediation and restructuring. Ultimately, the study's outcomes could guide the development of specific rehabilitation programs centered on facial emotion recognition, emotional deficits, and emotional dysregulation in insomnia.

Read the detailed description

Methods Each group will undergo two facial emotion recognition tests, one under controlled conditions with unlimited time (explicit memory recognition) and the other using eye-tracking to assess attentional biases (implicit memory recognition). The two groups will then be compared to determine differences in facial emotion recognition abilities between insomnia and control groups (primary outcome). The study will also explore the same abilities using eye-tracking (considering attentional deficits and visual fixation) and compare the results based on emotional regulation profiles (considering the potential impact of emotional dysregulation, which is more frequently described in insomnia).

Data will be collected by a physician using paper-based questionnaires and entered into an anonymized database on the hospital's restricted network drive. The anonymized participant code will consist of the first letter of the first name, first letter of the last name, group (0: controls/1: insomnia), and inclusion number (e.g., JG-0-001). This research project will be conducted in collaboration with the Adult Psychiatry Service, the Sleep Center, and the Ophthalmology Service at Angers University Hospital and will be part of the Laboratory of Psychology of the Pays de la Loire (LPPL - Research Unity 4638).

03

Conditions studied

  • Chronic Insomnia

Keywords

  • chronic insomnia
  • neuropsychology
  • facial expression assessment
  • emotional regulation
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Pre-inclusion criteria

  • Age between 18 and 65
  • Signed consent to participate in the study
  • Person affiliated to or benefiting from a social security scheme
  • For insomnia group: known insomnia (patient treated for insomnia)

Inclusion criteria:

  • Insomnia group: ISI >14 (between 15 and 28 = clinical insomnia)
  • Control group: ISI \< 8 (between 0 and 7 = no insomnia)

Non-pre-inclusion criteria

  • Known psychiatric disorders (Characterized depressive episode, Bipolar disorder, Schizophrenia and other delusional disorders, Specified anxiety disorder (social anxiety, generalized anxiety disorder), Obsessive-compulsive disorder (OCD), Eating disorders, Neurodevelopmental disorders (ASD, ADHD), Active addictive disorders (excluding tobacco), ...)
  • Taking antidepressant, neuroleptic or thymoregulator medication
  • Taking a benzodiazepine with a long half-life (>12 hours)
  • Condition requiring hospitalization in the month preceding the study
  • Known sequelae or progressive neurological disease
  • Known significant ophthalmological condition
  • Pregnancy or breast-feeding
  • Person deprived of liberty by judicial or administrative decision
  • Person subject to a legal protection measure
  • Person under psychiatric care without consent
  • For control group: no known insomnia

Non-inclusion criteria :

- Psychiatric disorders identified during psychiatric interview

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    Insomnia

    Diagnostic Test: Facial emotion recognition test with and without eye-tracking and Cognitive Emotion Regulation. Questionnaire (CERQ)

  • Active comparator
    Control

    Diagnostic Test: Facial emotion recognition test with and without eye-tracking and Cognitive Emotion Regulation. Questionnaire (CERQ)

Interventions

  • Diagnostic testFacial emotion recognition test with and without eye-tracking and Cognitive Emotion Regulation. Questionnaire (CERQ)

    Facial emotion recognition test without eye-tracking (explicit test, without time limit) and facial emotion recognition test with eye tracking (implicit test, with observation of fixation points)

06

What researchers measure

Primary outcomes

  1. Facial emotion recognition test (TREF test) in insomnia and control

    The error rate on facial recognition test (in percent)

    Time frame: 10 minutes

  2. Facial emotion recognition test (TREF test) in insomnia and control

    The intensity of the emotion on facial recognition test (in percent)

    Time frame: 10 minutes

  3. Facial emotion recognition test (TREF test) in insomnia and control

    Response time on facial recognition test (in second)

    Time frame: 10 minutes

Secondary outcomes

  1. Attentional bias

    Measurement of errors rate on facial recognition test (TREF test) with eye-tracking dispositif (in percent)

    Time frame: 10 minutes

  2. Attentional bias

    Intensity of the recognized emotion on facial recognition test in eye-tracking (in percent)

    Time frame: 10 minutes

  3. Attentional bias

    Measurement of first fixation duration on facial recognition test in eye-tracking (in second)

    Time frame: 10 minutes

  4. Attentional bias

    Measurement of duration of fixation on eyes (of face photography in the test) on facial recognition test in eye-tracking

    Time frame: 10 minutes

  5. Attentional bias

    Measurement of duration of fixation on nose (of face photography in the test) on facial recognition test in eye-tracking

    Time frame: 10 minutes

  6. Attentional bias

    Measurement of duration of fixation on mouth (of face photography in the test) on facial recognition test in eye-tracking

    Time frame: 10 minutes

  7. Emotional dysregulation bias

    Cognitive Emotional Regulation Questionnaire (CERQ) test. The CERQ is made up of 36 assertions with multiple related propositions i.e. "almost never, sometimes, regularly, often, almost always" corresponding to a score between 1 and 5. It identifies two main types of emotional regulation strategy profile according to the scores obtained on the various questions, each ranging from 4 to 20 : measures adaptive regulation (sub-types: acceptance, positive centering, action centering, positive re-evaluation, perspective-taking) and non-adaptive regulation (sub-types: self-blame, rumination, catastrophism, blaming others). others).

    Time frame: 5 minutes

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Sep 2027, 21 months after the start.

Of 1,219 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 21 months is above that.

Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2024
First posted
Feb 9, 2024
StartActual
Dec 12, 2025
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06251258
Responsible party
Sponsor
First posted
Feb 9, 2024
Start date
Dec 12, 2025
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Apr 6, 2026

Study contacts

Benedicte GOHIER
Contact
BeGohier@chu-angers.fr
02 41 35 32 44
Aurélie HAUTEFORT
Contact
aurelie.hautefort@chu-angers.fr
0763947304

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion